Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Oxford Biomedica plc. (5/6/22). "Press Release: Oxford Biomedica Solutions Announces Novel Dual Plasmid Transfection System". Bedford, MA.

Organisations Organisation Oxford Biomedica Solutions LLC
  Group Oxford Biomedica (Group)
  Organisation 2 American Society of Gene and Cell Therapy (ASGCT)
Products Product Dual Plasmid Transfection System (Oxford Biomedica)
  Product 2 ASGCT 2022 Washington DC
Person Person Kelly, Tim (Oxford Biomedica 202203 CEO of Oxford Biomedica Solutions)

Oxford Biomedica Solutions announces novel Dual Plasmid Transfection System, and has demonstrated suspension bioreactor titers above E15 vg/L, and chromatography purification achieving 90% fully in-tact vector

Oxford Biomedica Solutions, LLC. (“Oxford Biomedica Solutions”), a new high-performing, full scope AAV manufacturing and innovation business, now offering its ‘Plug & Play’ Platform that has successfully delivered four GMP programs and five Investigational New Drug submissions. Oxford Biomedica Solutions is announcing today that it will be sharing novel and critical Platform data, and the new Dual Plasmid Solution, at the upcoming ASGCT annual meeting, May 16-19, Washington D.C.

The gene therapy space continues to need higher performing manufacturing processes, and more importantly, higher quality vector. The Oxford Biomedica Solutions team have been innovating to develop the capability to deliver both quantity and quality.

Tim Kelly, CEO of Oxford Biomedica Solutions said “This new Dual Plasmid Solution is really a game changer for Companies who are looking for high quality vector and performance. We are now able to achieve 2E17 vector genomes in a single 500L drug substance lot, which will also allow access to much larger indications.”

Poster presentation details for the event:
Tuesday May 17 from 5:30-6:30 pm
Poster board number Tu-267
Abstract number 762


Oxford Biomedica Solutions:
Tim Kelly, Chief Executive Officer:

About Oxford Biomedica Solutions

Oxford Biomedica Solutions is a high-performing, full scope AAV manufacturing and innovation business based near Boston, Massachusetts, US.

The newly formed company has approximately 125 technical operation employees based at its state-of-the-art AAV manufacturing facility with approximately 25,000 sq. ft of GMP space. It operates three 500L bioreactors using a proprietary serum-free suspension process for clinical manufacturing via a proprietary ‘plug and play’ platform. The GMP experience includes 45 successful 500L lots, and the production process has proven scalability to 2000L in the high-quality process development laboratories

Oxford Biomedica Solutions is owned by Oxford Biomedica plc together with Homology Medicines Inc.

Record changed: 2023-06-14


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for Oxford Biomedica (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top